MA29839B1 - Derives de carboxamides servant d'antagonistes des recepteurs muscariniques - Google Patents

Derives de carboxamides servant d'antagonistes des recepteurs muscariniques

Info

Publication number
MA29839B1
MA29839B1 MA30766A MA30766A MA29839B1 MA 29839 B1 MA29839 B1 MA 29839B1 MA 30766 A MA30766 A MA 30766A MA 30766 A MA30766 A MA 30766A MA 29839 B1 MA29839 B1 MA 29839B1
Authority
MA
Morocco
Prior art keywords
antagonists
muscarinic receptors
carboxamide derivatives
muscarinic
carboxamide
Prior art date
Application number
MA30766A
Other languages
English (en)
Inventor
Paul Alan Glossop
Simon John Mantell
Ross Sinclair Strang
Christine Anne Louise Watson
Anthony Wood
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of MA29839B1 publication Critical patent/MA29839B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Dérivés de carboxamides servant d'antagonistes des récepteurs muscariniques La présente invention concerne des composés de formule des procédés et intermédiaires pour leur préparation, leur utilisation comme antagonistes muscariniques, et des compositions pharmaceutiques les contenant.
MA30766A 2005-09-21 2008-03-19 Derives de carboxamides servant d'antagonistes des recepteurs muscariniques MA29839B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71947705P 2005-09-21 2005-09-21
US71946805P 2005-09-21 2005-09-21
US71946705P 2005-09-21 2005-09-21

Publications (1)

Publication Number Publication Date
MA29839B1 true MA29839B1 (fr) 2008-10-03

Family

ID=37698323

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30766A MA29839B1 (fr) 2005-09-21 2008-03-19 Derives de carboxamides servant d'antagonistes des recepteurs muscariniques

Country Status (43)

Country Link
US (3) US7772223B2 (fr)
EP (1) EP1928821B1 (fr)
JP (1) JP4221447B1 (fr)
KR (1) KR100976909B1 (fr)
CN (1) CN101268046B (fr)
AP (1) AP1983A (fr)
AR (1) AR055171A1 (fr)
AT (1) ATE420069T1 (fr)
AU (1) AU2006293618B9 (fr)
BR (1) BRPI0616111B8 (fr)
CA (1) CA2623332C (fr)
CR (2) CR9814A (fr)
CU (1) CU20100115A7 (fr)
CY (1) CY1108880T1 (fr)
DE (1) DE602006004768D1 (fr)
DK (1) DK1928821T3 (fr)
DO (1) DOP2006000202A (fr)
EA (1) EA013083B1 (fr)
EC (1) ECSP088265A (fr)
ES (1) ES2318794T3 (fr)
GE (1) GEP20104880B (fr)
GT (1) GT200600422A (fr)
HK (1) HK1117163A1 (fr)
HN (1) HN2006032615A (fr)
HR (1) HRP20090127T3 (fr)
IL (1) IL189453A (fr)
MA (1) MA29839B1 (fr)
ME (1) ME01106B (fr)
MX (1) MX2008002805A (fr)
MY (1) MY143581A (fr)
NL (1) NL2000241C2 (fr)
NO (1) NO340975B1 (fr)
NZ (1) NZ566023A (fr)
PE (1) PE20070460A1 (fr)
PL (1) PL1928821T3 (fr)
PT (1) PT1928821E (fr)
RS (2) RS50855B (fr)
SI (1) SI1928821T1 (fr)
TN (1) TNSN08137A1 (fr)
TW (1) TWI322143B (fr)
UY (1) UY29798A1 (fr)
WO (1) WO2007034325A1 (fr)
ZA (1) ZA200801432B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008002246A1 (fr) * 2006-06-28 2008-01-03 Astrazeneca Ab Composition pharmaceutique comprenant un inhibiteur de la ikk2 et un second ingrédient actif
US20100160279A1 (en) * 2006-09-22 2010-06-24 Pfizer Inc Azetidine Derivatives as Muscarinic Receptor Antagonists
US8263583B2 (en) * 2007-03-16 2012-09-11 Pfizer Limited Hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide
JP5801997B2 (ja) 2009-07-07 2015-10-28 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器
EP2609065B1 (fr) * 2010-08-26 2015-07-08 Albemarle Corporation Procédés de production de 1-bromo-2 (cyclopropyl méthoxy)-5 fluoro-4- méthoxybenzène
CN103242214B (zh) * 2013-05-02 2016-04-06 陕西步长高新制药有限公司 一种吲哚衍生物及其制备方法
KR101538846B1 (ko) 2013-07-30 2015-07-22 동아에스티 주식회사 신규한 바이페닐 유도체 및 그의 제조방법
EP3596046A1 (fr) * 2017-03-15 2020-01-22 Mylan Laboratories Ltd. Nouveaux polymorphes de chlorhydrate de (5-[3-(3-hydroxyphénoxy) azétidin-1-yl]-5-méthyl-2,2-diphénylhexanamide
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN114732910A (zh) 2017-10-05 2022-07-12 弗尔康医疗公司 P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd
CN111423434A (zh) * 2019-01-09 2020-07-17 四川海思科制药有限公司 一种碳酰胺衍生物及其制备方法
WO2020261160A1 (fr) * 2019-06-25 2020-12-30 Mylan Laboratories Limited Procédés et intermédiaires pour la préparation de sel de chlorhydrate de 5- [3-(3-hydroxyphénoxy)azétidine-1-yl]-5-méthyl-2,2-diphénylhexanamide
WO2021260441A1 (fr) 2020-06-26 2021-12-30 Mylan Pharma Uk Limited Formulations comprenant du (5-[3-(3-hydroxyphénoxy)azétidin-1-yl]-5-méthyl-2,2-diphénylhexanamide
WO2023049696A1 (fr) * 2021-09-21 2023-03-30 Corteva Agriscience Llc Méthylation de 2-chloro-6-fluorophénol

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2886574A (en) * 1956-11-19 1959-05-12 Upjohn Co Quaternary ammonium salts of 2, 2-diphenyl-4, 4-dimethyl-4-pyrrolidino-butyramide
US4219559A (en) * 1979-01-10 1980-08-26 Janssen Pharmaceutica N.V. N-Heterocyclyl-4-piperidinamines
GB8824262D0 (en) * 1988-10-17 1988-11-23 Pfizer Ltd Therapeutic agents
US5070087A (en) * 1989-05-08 1991-12-03 A. H. Robins Company, Incorporated Aryl(alkyland alkylene)-N-((phenoxy and phenylthio)alkyl) aminoheterocyclics as cardiovascular, anthihistaminic, antisecretory and antiallergy agents
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
DE69720518T2 (de) * 1996-12-02 2004-02-26 Kyorin Pharmaceutical Co., Ltd. Neue derivate von n-substituierten pyrrolidin derivaten und deren herstellungsverfahren
DE59611439D1 (de) * 1996-12-17 2007-09-06 Filtertek Bv Rückschlagventil, insbesondere für die Medizintechnik
JPH11100366A (ja) * 1997-09-29 1999-04-13 Kyorin Pharmaceut Co Ltd 新規ｎ−置換環状アミン誘導体及びその製造法
US6673908B1 (en) * 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
GB0011838D0 (en) 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
EA006505B1 (ru) 2001-12-20 2005-12-29 Лабораториос С.А.Л.В.А.Т.,С.А. Производные карбамата 1-алкил-1-азониабицикло[2.2.2]октана и их применение в качестве антагонистов мускаринового рецептора
MXPA03000145A (es) 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
EP1375508A1 (fr) 2002-06-27 2004-01-02 Aventis Pharma Deutschland GmbH Dérivés de l'adénosine N6-substitués et leur utilisation comme médicament
RU2005111589A (ru) 2002-09-17 2006-01-20 Актелион Фармасьютиклз Лтд. (Ch) Производные 1-пиридин-4-илмочевины

Also Published As

Publication number Publication date
ZA200801432B (en) 2009-07-29
RS51680B (en) 2011-10-31
RS50855B (sr) 2010-08-31
CN101268046B (zh) 2012-07-25
WO2007034325A1 (fr) 2007-03-29
AU2006293618B9 (en) 2009-10-29
ME01106B (me) 2013-03-20
JP4221447B1 (ja) 2009-02-12
US7772223B2 (en) 2010-08-10
KR20080037103A (ko) 2008-04-29
NO20081001L (no) 2008-03-25
NL2000241C2 (nl) 2009-01-05
US8268881B2 (en) 2012-09-18
BRPI0616111B8 (pt) 2021-05-25
BRPI0616111A2 (pt) 2011-06-07
US20070105831A1 (en) 2007-05-10
CY1108880T1 (el) 2014-07-02
EA200800540A1 (ru) 2008-08-29
GEP20104880B (en) 2010-01-11
HK1117163A1 (en) 2009-01-09
GT200600422A (es) 2007-05-28
PL1928821T3 (pl) 2009-06-30
CR9814A (es) 2008-04-16
CA2623332C (fr) 2012-05-01
IL189453A (en) 2014-06-30
PT1928821E (pt) 2009-03-10
CN101268046A (zh) 2008-09-17
DE602006004768D1 (de) 2009-02-26
ECSP088265A (es) 2008-04-28
ES2318794T3 (es) 2009-05-01
AR055171A1 (es) 2007-08-08
RS20080119A (en) 2009-05-06
JP2009508933A (ja) 2009-03-05
US20100029720A1 (en) 2010-02-04
NL2000241A1 (nl) 2007-03-22
TNSN08137A1 (fr) 2009-07-14
SI1928821T1 (sl) 2009-04-30
AP1983A (en) 2009-03-24
CU23910B1 (fr) 2013-06-29
US20110251164A1 (en) 2011-10-13
US8486992B2 (en) 2013-07-16
TW200745024A (en) 2007-12-16
CU20100115A7 (es) 2011-10-14
NZ566023A (en) 2010-02-26
AU2006293618B2 (en) 2009-10-08
HN2006032615A (es) 2010-10-04
MY143581A (en) 2011-05-31
NO340975B1 (no) 2017-07-31
IL189453A0 (en) 2008-08-07
CR20130209A (es) 2013-09-19
TWI322143B (en) 2010-03-21
EA013083B1 (ru) 2010-02-26
AU2006293618A1 (en) 2007-03-29
PE20070460A1 (es) 2007-05-14
DOP2006000202A (es) 2007-04-15
EP1928821A1 (fr) 2008-06-11
DK1928821T3 (da) 2009-03-16
CA2623332A1 (fr) 2007-03-29
EP1928821B1 (fr) 2009-01-07
UY29798A1 (es) 2007-04-30
MX2008002805A (es) 2008-04-07
KR100976909B1 (ko) 2010-08-18
BRPI0616111B1 (pt) 2019-10-08
HRP20090127T3 (en) 2009-06-30
ATE420069T1 (de) 2009-01-15

Similar Documents

Publication Publication Date Title
MA29839B1 (fr) Derives de carboxamides servant d'antagonistes des recepteurs muscariniques
MA30778B1 (fr) Derives de sulfonamides servant d'agonistes adrenergique et d'antagonistes muscariniques
MA31087B1 (fr) Derives d'amide et d'ester d'indazolyle pour traiter des troubles medies par le recepteur de glucocorticoïde.
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
MA30289B1 (fr) Dérivés d'amines
TN2009000524A1 (en) Novel dicarboxylic acid derivatives as s1p1 receptor agonists
MA32615B1 (fr) Inhibiteurs de cmet
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
TNSN05202A1 (fr) Indolone-oxazolidinones antibacteriennes, intermediaires pour leur preparation et compositions pharmaceutiques les contenant
MA31521B1 (fr) Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central
BRPI0507495A (pt) composto, composição farmacêutica, uso do composto método para o tratamento de distúrbios mediados por mglur5, e, método para inibir a ativação de receptores de mglur5
MA31419B1 (fr) Derives de pyridine
ATE464304T1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonist n
FR2838439B1 (fr) Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant
MA27840A1 (fr) Derives de (2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propylphenyle servant d'agonistes beta2
EP2202222A3 (fr) Dérivés d'indène, leur préparation et leur utilisation en tant que médicaments
WO2004089366A8 (fr) Composes bicycliques comme antagonistes du recepteur nr2b
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA33131B1 (fr) Nouveaux derives de benzothiadiazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MA30703B1 (fr) Dérivés de 5,6-bisaryl-2-pyridine-carboxamide, leur préparation et leur application en thérapeutique comme antagonistes des recepteurs a l'urotensine ii.
MA27852A1 (fr) Derives de 1-(alkylaminoalkyl-pyrolidin-/piperidinyl)-2,2-diphenylacetamide utilises comme antagonistes du recepteur muscarinique
TN2009000470A1 (fr) Derives d'azetidine et leur utilisation comme antagonistes de prostaglandine e2
MA31863B1 (fr) Dérivés de pyrazole comme inhibiteurs de 5-lo
MA31359B1 (fr) Pyrimidinyl-pipérazines utiles en tant que ligands des récepteurs d3/d2